Introduction
Intratumoral heterogeneity is a defining feature of human cancers and a primary driver of therapeutic resistance. Conventional in vitro models fail to capture the dynamic interplay between co-existing subclones, while xenograft models established from immortalized cell lines often represent a homogenized tumor population. In contrast, patient-derived xenografts (PDX) conserve clonal diversity and enable researchers to observe evolutionary processes as tumors adapt to selective pressures such as chemotherapy, targeted agents, or immunotherapies. These systems therefore provide a powerful experimental framework for dissecting clonal competition, evolutionary bottlenecks, and emergent resistance mechanisms in vivo.
The Basis of Tumor Heterogeneity
Tumors arise from the accumulation of genetic, epigenetic, and transcriptomic alterations across multiple cellular lineages. This leads to the coexistence of genetically distinct clones within the same tumor mass. Subclonal architecture is further influenced by extrinsic factors including the tumor microenvironment, hypoxic gradients, and stromal–immune interactions. As therapies are applied, selective pressures lead to clonal sweeps, where resistant subclones expand at the expense of sensitive populations.
PDX as a Platform for Clonal Evolution Studies
PDX models preserve these diverse clonal populations, allowing direct longitudinal tracking of tumor evolution. High-throughput sequencing and single-cell profiling of early versus late passages reveal both conserved features and adaptive shifts. Importantly:
Lineage Tracing: Genetic barcoding or CRISPR-based lineage marking in PDX enables precise quantification of clonal competition.
Selective Expansion of Resistant Subclones: Treatment with EGFR inhibitors in PDX models of non-small cell lung cancer demonstrates the emergence of resistant clones harboring secondary mutations (e.g., T790M).
Microenvironmental Shaping: Engraftment into murine hosts introduces new selective pressures, including stromal replacement and altered vascularization, which can influence subclone fitness.
Experimental Approaches
Serial Passaging: Studying clonal drift across multiple passages to differentiate intrinsic tumor evolution from host-driven changes.
Single-Cell Sequencing: Mapping clonal diversity before and after treatment exposure.
Spatial Transcriptomics: Visualizing subclonal distributions within tumor architecture.
Mathematical Modeling: Computational frameworks simulating evolutionary trajectories in vivo.
Applications and Implications
Understanding intratumoral heterogeneity through PDX provides insights critical for drug development. It enables prediction of resistance pathways, identification of subclones responsible for relapse, and evaluation of combination therapies designed to suppress multiple tumor lineages simultaneously. By mapping clonal evolution under therapeutic pressure, PDX models inform rational trial design and the development of precision treatment strategies targeting both dominant and minor subclones.
Future Perspectives
As sequencing costs decline and single-cell methodologies mature, clonal evolution studies in PDX will become increasingly refined. Integration of multi-omics with machine learning algorithms promises predictive modeling of subclonal dynamics. Moreover, coupling humanized immune PDX systems with heterogeneity-focused assays will reveal how immune pressures further sculpt tumor evolution. Ultimately, these efforts will accelerate the development of adaptive therapeutic regimens designed to pre-empt resistance and improve long-term patient outcomes.